What is Ertugliflozin 15 mg used for?

Ertugliflozin 15 mg is indicated for Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Who makes Ertugliflozin 15 mg?

Ertugliflozin 15 mg is developed by Pfizer.

What development phase is Ertugliflozin 15 mg in?

Ertugliflozin 15 mg is FDA-approved (marketed).

What are the side effects of Ertugliflozin 15 mg?

Common side effects include Upper respiratory tract infection, Hypoglycaemia, COVID-19, Nasopharyngitis, Headache, Gastritis.

What is the generic name of Ertugliflozin 15 mg?

ertugliflozin-15-mg is the generic (nonproprietary) name of Ertugliflozin 15 mg.

Last reviewed 2026-04-20 · How we verify

Ertugliflozin 15 mg (ertugliflozin-15-mg)

Pfizer · FDA-approved approved Small molecule Quality 44/100

Ertugliflozin 15 mg, developed by Pfizer Inc., is a medication used to treat type 2 diabetes mellitus and reduce cardiovascular events. It works by inhibiting the SGLT2 protein, which is involved in glucose reabsorption in the kidneys. This leads to increased glucose excretion in the urine, resulting in improved glycemic control. Ertugliflozin has been shown to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. The medication has been commercially successful, generating $7,366 million in revenue. With 14 clinical trials and 30 publications, the efficacy and safety of ertugliflozin have been extensively studied. Its mechanism of action and clinical benefits make it a valuable treatment option for patients with type 2 diabetes.

At a glance

Generic name	ertugliflozin-15-mg
Sponsor	Pfizer
Drug class	SGLT2 inhibitor
Target	SGLT2
Modality	Small molecule
Therapeutic area	Metabolic
Phase	FDA-approved

Approved indications

Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Common side effects

Upper respiratory tract infection
Hypoglycaemia
COVID-19
Nasopharyngitis
Headache
Gastritis
Pyrexia
Influenza
Gastroenteritis
Nausea
Abdominal pain
Vomiting

Drug interactions

Warfarin
Insulin
Sulfonylureas
Pioglitazone
Rosiglitazone
Empagliflozin
Dapagliflozin
Canagliflozin
Corticosteroids
Nonsteroidal anti-inflammatory drugs (NSAIDs)
ACE inhibitors
Angiotensin II receptor blockers (ARBs)

Key clinical trials

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059) (PHASE3)
DESIGN (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ertugliflozin 15 mg CI brief — competitive landscape report
Ertugliflozin 15 mg updates RSS · CI watch RSS
Pfizer portfolio CI